Literature DB >> 7080958

Protein binding and clearance of oxaprozin, a highly bound anti-inflammatory agent.

C A Homon, E R Fluck, F W Janssen, H W Ruelius.   

Abstract

Conventional dialysis cells were used in initial attempts to determine the binding characteristics of oxaprozin (4,5-diphenyl-2-oxazolepropionic acid, Wy-21,743). Equilibration required dialysis times up to 22 hours at 37 degrees C resulting in deterioration of plasma proteins, which in turn leads to highly variable binding values. In contrast, dialysis with Dianorm cells requires less than 4 hours to reach equilibrium. The configuration of the cell optimizes the contact between the solutes and the membrane and allows for a more efficient mixing and exchanging of the solute. The percentage of unbound drug was linearly related to total drug in human plasma samples to which oxaprozin in clinically relevant concentrations (55-405 micrograms/ml) had been added. Likewise, a linear relationship between total drug concentration and the percentage unbound was observed in specimens from a pharmacokinetic study in healthy volunteers. Clearance of total oxaprozin from plasma correlated with the percentage unbound drug. Thus the higher clearance observed under steady-state conditions (where concentrations are higher than following single dose administration) was caused by a larger unbound fraction available to the elimination sites.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7080958     DOI: 10.1007/BF01965148

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  7 in total

1.  Disposition of 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin) in beagle dogs and rhesus monkeys.

Authors:  F W Janssen; S K Kirkman; J A Knowles; H W Ruelius
Journal:  Drug Metab Dispos       Date:  1978 Jul-Aug       Impact factor: 3.922

Review 2.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

Review 3.  The binding of drugs by plasma proteins.

Authors:  M C Meyer; D E Guttman
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

4.  Anti-inflammatory properties of 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin).

Authors:  M E Rosenthale; A J Begany; A Dervinis; J L Malis; D A Shriver; S L Datko; M I Gluckman
Journal:  Agents Actions       Date:  1974-08

5.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

6.  Metabolism and kinetics of oxaprozin in normal subjects.

Authors:  F W Janssen; W J Jusko; S T Chiang; S K Kirkman; P J Southgate; A J Coleman; H W Ruelius
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

7.  Diaryloxazole and diarylthiazolealkanoic acids: two novel series of non-steroidal anti-inflammatory agents.

Authors:  K Brown; J F Cavalla; D Green; A B Wilson
Journal:  Nature       Date:  1968-07-13       Impact factor: 49.962

  7 in total
  3 in total

Review 1.  Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of oxaprozin.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

3.  Oxaprozin pharmacokinetics in the elderly.

Authors:  D J Greenblatt; R Matlis; J M Scavone; G T Blyden; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.